ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023
Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology.
Open access · bronzeAbstract read
In one paragraph
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- Astrocyte-driven small vessel disease is an early, amyloid-independent feature of PSEN1 E280A familial Alzheimer's disease.bioRxiv : the preprint server for biology · 2026Article
- Evaluation of Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid, Serum, and Plasma Using the Fully Automated Lumipulse Platform.Journal of clinical laboratory analysis · 2026Article
- The MMP-9/TIMP-1 Ratio and Concentrations of Osteopontin Are Elevated in Cerebrospinal Fluid of People With Multiple Sclerosis and Decrease After Autologous Hematopoietic Stem Cell Transplantation.Annals of clinical and translational neurology · 2026Article
- Plasma p-tau217 predicts PET-based pathological staging for precision Alzheimer disease assessment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Diagnostic performance of Alzheimer's disease blood and CSF biomarkers in a Brazilian cohort with low educational attainment.Molecular psychiatry · 2025Article
- Altered triple network model connectivity is associated with cognitive function and depressive symptoms in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Observational
- Increased PlasmaJournal of the American Heart Association · 2024Article
- iPSC-derived blood-brain barrier modeling reveals APOE isoform-dependent interactions with amyloid beta.Fluids and barriers of the CNS · 2024Article
- Cardiometabolic multimorbidity, peripheral biomarkers, and dementia in rural older adults: The MIND-China study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Blood-brain barrier disruption: a culprit of cognitive decline?Fluids and barriers of the CNS · 2024Review
- Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia.Neurology · 2024Article
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease.Nature communications · 2024Article
- Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Protein fibril aggregation on red blood cells: a potential biomarker to distinguish neurodegenerative diseases from healthy aging.Brain communications · 2024Article
- Blood phosphorylated Tau181 reliably differentiates amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum: A systematic review and meta-analysis.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 10 institutions in 6 countries.
Bruna BellaverDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Albert Puig-PijoanCognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain.
João Pedro Ferrari-SouzaDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Douglas T LeffaDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Firoza Z LussierDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Pamela C L FerreiraDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Cécile TissotTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Guilherme PovalaDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Joseph TherriaultTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Andréa L BenedetDepartment of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Stijn ServaesTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Mira ChamounTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Jenna StevensonTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Nesrine RahmouniTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Marie VermeirenTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Arthur C MacedoTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Aida Fernández-LebreroCognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain.
Greta García-EscobarIMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
Irene Navalpotro-GómezCognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain.
Oscar LopezDepartment of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Dana L TudorascuDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ann CohenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Victor L VillemagneDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
William E KlunkDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Serge GauthierTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Eduardo R ZimmerGraduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Thomas K KarikariDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Marc Suárez-CalvetCognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain.ORCID 0000-0002-2993-569X
Pedro Rosa-NetoTranslational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Tharick A PascoalDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
University of Pittsburgh · USDouglas Mental Health University Institute · CAUniversidade Federal do Rio Grande do Sul · BRPasqual Maragall Foundation · ESSahlgrenska University Hospital · SEHospital Del Mar · ESKing's College London · GBUniversitat Autònoma de Barcelona · ESUniversitat Pompeu Fabra · ESUniversity of Gothenburg · SE
Funding
Longitudinal multicenter head-to-head harmonization of tau PET tracersR01AG073267 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAKER, SUZANNE L, PASCOAL, THARICK · 2021 to 2025
$41.1MHead-to-head comparisons of high-performance plasma phospho-tau epitopes for the detection of Alzheimer's diseaseR01AG075336 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Tharick Pascoal · 2022 to 2026
$3.7MNIA NIH HHS R01 AG073267NIA NIH HHS R01 AG075336
Abstract
introductionAmyloid-β (Aβ) and tau can be quantified in blood. However, biological factors can influence the levels of brain-derived proteins in the blood. The blood-brain barrier (BBB) regulates protein transport between cerebrospinal fluid (CSF) and blood. BBB altered permeability might affect the relationship between brain and blood biomarkers.
methodsWe assessed 224 participants in research (TRIAD, n = 96) and clinical (BIODEGMAR, n = 128) cohorts with plasma and CSF/positron emission tomography Aβ, p-tau, and albumin measures.
resultsPlasma Aβ DISCUSSION: These findings suggest that BBB integrity may influence the performance of plasma Aβ, but not p-tau, biomarkers in research and clinical settings. HIGHLIGHTS: BBB permeability affects the association between brain and plasma Aβ levels. BBB integrity does not affect the association between brain and plasma p-tau levels. Plasma Aβ was most affected by BBB permeability in AD-related brain regions. BBB permeability increases with age but not according to cognitive status.
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersBlood-Brain BarrierBrainHumansPeptide FragmentsPositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseaseamyloid-βblood biomarkersblood-brain barrierconfounding factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.